Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00513617 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of Arginine as a Treatment for Sickle Cell Anemia
A Phase 2 study, sponsored by UCSF Benioff Children's Hospital Oakland.
- Completed
- Registry status
- Phase 2
- Development phase
- 128
- Enrollment target
NCT00513617: Completed Phase 2 study, sponsored by UCSF Benioff Children's Hospital Oakland.
NCT00513617 is a Phase 2 study that has completed, run by UCSF Benioff Children's Hospital Oakland. The registered enrollment target is 128 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00513617, a Phase 2 study, has completed, sponsored by UCSF Benioff Children's Hospital Oakland.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 128 participants
- Enrollment target
Study Summary
Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited genetic disease that can cause intense pain episodes. This study will evaluate the effectiveness of the nutritional supplement arginine at improving blood cell function and disease symptoms in people with SCD.
Interventions
- DRUG Placebo
- DRUG Arginine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2004-06 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00513617
The ClinicalTrials.gov registry entry for NCT00513617 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCSF Benioff Children's Hospital Oakland, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00513617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00513617 about?
NCT00513617 is a clinical study titled "Effectiveness of Arginine as a Treatment for Sickle Cell Anemia". Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited genetic disease that can cause intense pain episodes. This study will evaluate the effectiveness of the nutritional supplement arginine at improving blood cell function and disease symptoms in people with SCD.
What is the current status of trial NCT00513617?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 128 participants. The study started on 2004-06. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00513617?
The interventions under investigation include: Placebo (DRUG), Arginine (DRUG).
Who is sponsoring clinical trial NCT00513617?
This trial is sponsored by UCSF Benioff Children's Hospital Oakland, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.